Johnny Tang1, Ashley A Herda2, Timothy S Kern3. 1. Department of Ophthalmology, University of Kansas Medical Center, Prairie Village, Kansas, USA Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA. 2. Department of Ophthalmology, University of Kansas Medical Center, Prairie Village, Kansas, USA. 3. Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Abstract
PURPOSE: Far-red/near-infrared phototherapy or photobiomodulation (PBM) has recently been reported to be an effective and non-invasive treatment method to inhibit lesions of diabetic retinopathy (DR) in animals. This study investigated the safety and efficacy of PBM in diabetic patients to treat non-center-involving diabetic macular oedema (NCDME). METHODS: This was a non-randomised, consecutive, case series, where 4 patients with type 2 diabetes with NCDME were treated for 160 s per day with PBM for 2-9 months. Demographic data including age, sex, HbA1c%, electronic ETDRS visual acuity, and retinal and macular thickness were measured using spectral domain ocular coherence tomography (SD-OCT) before and after treatment. RESULTS: Four eyes of 4 patients were treated, with fellow eyes serving as untreated controls. Daily PBM treatment for only 80 s per treatment twice daily caused a significant reduction in focal retinal thickening in all 4 treated eyes. No adverse effects attributable to therapy were noted by the patients or study investigators during the study period. CONCLUSIONS: PBM potentially offers a non-invasive and cost-effective therapeutic option for patients with NCDME. Further studies of this therapeutic option in DR are warranted. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
PURPOSE: Far-red/near-infrared phototherapy or photobiomodulation (PBM) has recently been reported to be an effective and non-invasive treatment method to inhibit lesions of diabetic retinopathy (DR) in animals. This study investigated the safety and efficacy of PBM in diabeticpatients to treat non-center-involving diabetic macular oedema (NCDME). METHODS: This was a non-randomised, consecutive, case series, where 4 patients with type 2 diabetes with NCDME were treated for 160 s per day with PBM for 2-9 months. Demographic data including age, sex, HbA1c%, electronic ETDRS visual acuity, and retinal and macular thickness were measured using spectral domain ocular coherence tomography (SD-OCT) before and after treatment. RESULTS: Four eyes of 4 patients were treated, with fellow eyes serving as untreated controls. Daily PBM treatment for only 80 s per treatment twice daily caused a significant reduction in focal retinal thickening in all 4 treated eyes. No adverse effects attributable to therapy were noted by the patients or study investigators during the study period. CONCLUSIONS:PBM potentially offers a non-invasive and cost-effective therapeutic option for patients with NCDME. Further studies of this therapeutic option in DR are warranted. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Magdalena G Krzystolik; Samara F Strauber; Lloyd Paul Aiello; Roy W Beck; Brian B Berger; Neil M Bressler; David J Browning; Robert B Chambers; Ronald P Danis; Matthew D Davis; Adam R Glassman; Victor H Gonzalez; Paul B Greenberg; Jeffrey G Gross; Judy E Kim; Craig Kollman Journal: Ophthalmology Date: 2007-03-13 Impact factor: 12.079
Authors: Johnny Tang; Yunpeng Du; Chieh Allen Lee; Ramaprasad Talahalli; Janis T Eells; Timothy S Kern Journal: Invest Ophthalmol Vis Sci Date: 2013-05-01 Impact factor: 4.799
Authors: Luis Santana-Blank; Elizabeth Rodríguez-Santana; Karin E Santana-Rodríguez; Heberto Reyes Journal: Photomed Laser Surg Date: 2016-02-18 Impact factor: 2.796
Authors: Judy E Kim; Adam R Glassman; Kristin Josic; Michele Melia; Lloyd P Aiello; Carl Baker; Janis T Eells; Lee M Jampol; Timothy S Kern; Dennis Marcus; Hani Salehi-Had; Sandeep N Shah; Daniel F Martin; Cynthia R Stockdale; Jennifer K Sun Journal: Ophthalmol Retina Date: 2021-10-08